(APLT) Applied Therapeutics - Ratings and Ratios

Applied Therapeutics Inc (NASDAQ:APLT) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious diseases with high unmet medical needs. The companys pipeline includes several promising candidates targeting validated molecular targets, with a primary focus on rare genetic disorders and diabetic complications.

The lead product candidate, AT-007, has completed Phase 3 trials for treating galactosemia, a rare genetic disorder, in both adults and children. Additionally, AT-007 is being explored for its potential in treating enzyme sorbitol dehydrogenase and phosphomannomutase enzyme-CDG. With a recent exclusive license and supply agreement with Mercury Pharma Group Limited, Applied Therapeutics is poised to commercialize AT-007, pending regulatory approvals.

The companys pipeline also includes AT-001, currently in Phase 3 clinical trials for diabetic cardiomyopathy and diabetic peripheral neuropathy, two significant complications arising from diabetes. Furthermore, AT-003 is in preclinical studies for diabetic retinopathy, another major diabetic complication. This diversified pipeline across various stages of development mitigates risk and presents multiple potential revenue streams.

From a technical analysis perspective, APLTs stock price has been volatile, with a 52-week range of $0.30 to $10.24. The current price of $0.46 is significantly lower than its SMA200 of $3.57, indicating a potential undervaluation. The ATR of 0.05, representing an 11.99% volatility, suggests that the stock is experiencing significant price movements. Given the SMA20 and SMA50 being close to the current price, a potential buy signal could emerge if the stock price consolidates above these moving averages.

Fundamentally, Applied Therapeutics has a market capitalization of $65.49M USD, with a Return on Equity (RoE) of 46.43%, indicating a strong potential for growth. The absence of a P/E ratio is typical for companies in the clinical-stage biopharmaceutical sector, as they often report negative earnings due to significant R&D expenses.

Forecasting the future performance of APLT involves analyzing both technical and fundamental data. If AT-007 receives regulatory approval and is successfully commercialized, it could significantly boost the companys revenue. Technically, a breakout above the SMA50 of $0.44, followed by a sustained move above the SMA20 of $0.43, could signal a bullish trend. Given the current ATR, a potential price target could be $0.60 in the short term, representing a 30% increase from the current price. However, this forecast is contingent upon positive clinical trial results, successful commercialization, and favorable market conditions.